Theranos Ethics Case Study

How to Actually Teach and Learn the Theranos Ethics Case Study Without Making It Boring

The Theranos Ethics Case Study is one of those topics that shows up in business school syllabi every single year, usually right after a semester gets heavy on corporate finance or organizational behavior. Students approach it expecting a straightforward fraud story, which it is, but the real value comes from how thoroughly you dissect it afterward. Most people stop at the headline numbers—$9 billion valuation, two decades of deception—and miss the structural ethics failures that actually made the company work for as long as it did. At its core, the case revolves around Elizabeth Holmes building a company around a diagnostic technology that didn't work, concealing that failure from investors, employees, and regulatory bodies, and then maintaining the lie through a combination of NDAs, intimidation, and performative innovation theater. But if you're using this as a teaching tool or studying it for professional development, you need to go deeper than the media narrative. The ethics failures aren't concentrated in one moment. They're distributed across multiple layers. Holmes herself made deliberate choices about what to disclose and what to hide. But the board members who stayed silent, the engineers who raised alarms and got pushed out, the investors who ignored red flags because the story was too compelling, the lab technicians who followed protocols they knew were inadequate—all of these are parts of the same ethical collapse. That's the first thing most students miss.

When I ran a workshop on this case for a group of senior management trainees last year, I had them map out each stakeholder's ethical obligation separately. One participant, a woman who'd worked in clinical diagnostics, pointed out something I hadn't considered before: the compliance officers at Theranos reportedly had the data showing the Edison device's inaccuracies but were structurally prevented from acting on it. Their ethical duty to patients existed in tension with their contractual duty to management, and the company's culture ensured the latter always won. That's a nuanced point that doesn't show up in most case summaries. Here's the practical angle most guides skip. If you're presenting this case in a professional setting, don't lead with the fraud. Lead with the technology. Show them the Edison machine photos, explain what it was supposed to do—a single drop of blood performing dozens of tests—then walk through the timeline of when the failures became undeniable versus when the company started hiding them. The gap between those two dates is where the ethics discussion actually lives. It wasn't a decision to cheat from day one. It was a series of incremental rationalizations, each one smaller and more defensible than the last. I've found that splitting the class into groups representing different stakeholders works better than a lecture format. Have one group role-play as investors who knew something was off but invested anyway, another as employees who discovered the truth mid-production cycle, and a third as board members with fiduciary duties they couldn't exercise effectively. The friction between those perspectives is where the learning happens. It also takes about 90 minutes instead of the usual 45, so plan accordingly.

What Most People Get Wrong About This Case

One common misunderstanding is treating Theranos as an outlier. It wasn't. The same dynamics appear in any high-stakes startup environment where the narrative becomes more important than the product. The "fake it till you make it" mentality isn't a personality quirk of entrepreneurs. It's a structural risk that compounds when combined with weak governance, information asymmetry, and regulatory gaps. The healthcare sector amplifies everything because the consequences of failure aren't financial—they're physiological. Another blind spot is assuming the regulatory system failed because it was too slow. The FDA actually took action. They inspected Theranos facilities and found significant deficiencies. The problem wasn't regulatory absence. It was enforcement capacity relative to the speed of a company operating across multiple jurisdictions with multiple product categories. By the time the FDA moved decisively, Theranos had already dissipated much of its capital and its key personnel had moved on. If you're teaching this, I'd recommend pairing it with the Uber or WeWork case studies. All three share the same pattern: a charismatic founder, a story that attracted capital, operational failures masked by creative accounting, and a governance structure designed to protect the founder rather than the stakeholders. The differences in industry and outcome matter, but the ethical mechanism is nearly identical.

There's also a practical limitation to keep in mind when using this case study. Some participants come in with a complete narrative already formed. They've watched the documentaries, read the books, seen the trial coverage. They don't need the facts presented to them. The challenge with that audience is getting past the entertainment value of the scandal and into the structural analysis. I handle this by skipping the background summary entirely and going straight to the harder questions: At what point did individual board members cross from negligent oversight to willful blindness? What would effective whistleblowing look like in a company with this kind of control over its employees? One edge case I keep running into is when people conflate the legal outcomes with the ethical ones. Holmes was convicted on fraud counts. That's a legal determination. The ethical question is broader and messier. Some people who were never charged still made ethically indefensible choices. The reverse is also true. A lab technician who followed orders she knew were wrong might bear less legal responsibility but equal ethical blame depending on your framework. If you're using this case for philosophy or ethics coursework rather than business law, spend more time on that distinction. The materials you'll need are straightforward. The Stanford Business School case report is the standard source. The DOJ prosecution documents are publicly available through court records. The FDA inspection reports, while less detailed than you might want, are accessible through FOIA requests. For classroom use, combining the case report with Walter Isaacson's biography and the John Carreyrou reporting gives you more than enough ground to cover. Don't try to add the Sundar Pichai testimony or the Securities and Exchange Commission filings unless you have extra time—the core case is dense enough on its own.

Bottom line: the Theranos Ethics Case Study isn't interesting because it's a wild story about a crazy founder. It's interesting because it shows exactly how ordinary ethical failures compound under the right conditions. If your discussion leaves people thinking about Holmes as the sole problem, you've missed the point. The case matters because the system around her did almost nothing to stop her until it was too late to stop anything at all.